Eszopiclone Patent Expiration
Eszopiclone is used for inducing hypnotic or sedative effects in humans. It was first introduced by Waylis Therapeutics Llc
Eszopiclone Patents
Given below is the list of patents protecting Eszopiclone, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Lunesta |
US6444673 (Pediatric) | Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it |
Aug 14, 2014
(Expired) | Waylis Therap |
| Lunesta | US6444673 | Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it |
Feb 14, 2014
(Expired) | Waylis Therap |
| Lunesta |
US6864257 (Pediatric) | Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it |
Mar 02, 2013
(Expired) | Waylis Therap |
| Lunesta | US6864257 | Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it |
Aug 30, 2012
(Expired) | Waylis Therap |
| Lunesta |
US6319926 (Pediatric) | Optically active 5H-pyrrolo[3, 4-B]pyrazine derivative, its preparation and pharmaceutical compositions containing it |
Jul 16, 2012
(Expired) | Waylis Therap |
| Lunesta |
US7381724 (Pediatric) | Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing same |
Jul 16, 2012
(Expired) | Waylis Therap |
Eszopiclone's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Eszopiclone:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Effects of Eszopiclone and Lemborexant in People With OSA With a Low Arousal Threshold Who Have Difficulty Sleeping | Flinders University | NA |
RECRUITING
(Sep 1, 2026)
| PHASE2 |
| National Adaptive Trial for PTSD Related Insomnia | VA Office of Research and Development | NA |
COMPLETED
(Jun 1, 2026)
| PHASE3 |
| Do Endotypes Predict Response and Sequelae in OSA Patients | University of California, San Diego | NA |
COMPLETED
(Jun 1, 2026)
| PHASE2 |
| Continuous Positive Airway Pressure, Arousability and Links to Mechanisms in Obstructive Sleep Apnea | Yale University | NA |
RECRUITING
(Jun 1, 2026)
| PHASE3 |